For the quarter ended June 2024, Neurocrine Biosciences (NBIX) reported revenue of $590.2 million, up 30.4% over the same period last year. EPS came in at $0.63, compared to $0.95 in the year-ago quarter. The reported revenue represents a surprise of +7.56% over the Zacks Consensus Estimate of $548.7 million. With the consensus EPS estimate being $1.15, the EPS surprise was -45.22%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $0.95 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -45.22%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $1.04 per share when it actually produced earnings of $0.42, delivering a surprise of -59.62%. Over the las ...

管理层变更 - 公司宣布首席执行官Kevin Gorman博士将于2024年10月11日退休,由目前的首席业务发展和战略官Kyle Gano博士接任[81] 临床试验进展 - 公司宣布NBI-1065845在成人重度抑郁症(MDD)II期SAVITRI™研究中取得积极的临床试验结果[81] - 公司宣布crinecerfont的新药申请获FDA优先审评,预计2024年12月29日和12月30日分别获批胶囊和口服溶液剂型[81] - 公司在内分泌学年会上发布crinecerfont III期CAHtalyst™注册研究的新数据,并在《新英格兰医学杂志》上发表了主要研究结果[81] - 公司启动了NBI-1070770成人MDD II期临床试验,以及NBI-1117567和NBI-1076968的I期临床试验[81] INGREZZA产品进展 - 公司INGREZZA获得美国医疗保险和医疗补助服务中心的特定小型制造商豁免,并推出了新的INGREZZA SPRINKLE颗粒剂型[82] - 公司上半年INGREZZA销售额同比增长27.6%,达到10.855亿美元,主要反映了强劲的患者需求和毛利率改善[83,85] 财务情况 - 公司上半年研发费用包括约3000万美元的合作里程碑费用[82] - 公司上半年研发费用增加,主要是由于早中期项目投入增加,以及合作里程碑费用增加[93,94] - 公司总现金、现金等价物和有价证券为16.767亿美元[106] - 公司总流动资产为16.698亿美元，总流动负债为3.985亿美元，总流动资金为12.713亿美元[106] - 公司2024年上半年经营活动产生的现金流为1.949亿美元,较去年同期增加[109] - 公司2024年上半年投资活动产生的现金流为-0.832亿美元,较去年同期有所减少[109] - 公司2024年上半年筹资活动产生的现金流为-2.231亿美元,较去年同期有所减少[109] - 公司2024年第二季度和上半年净收入分别为0.65亿美元和1.084亿美元[103][104] - 公司2024年上半年计提所得税费用为2.61亿美元[101] - 公司2024年上半年其他收益净额为-1.116亿美元,主要反映了2024年5月到期的2024年票据转换产生的1.384亿美元费用以及权益证券投资公允价值变动[100] - 公司认为现有资金和预期INGREZZA销售收入将足以满足未来12个月的资金需求[105] - 公司可能会寻求通过公开或私募股权市场、债务融资或战略联盟等方式获得额外资金[105]

产品销售 - INGREZZA第二季度净产品销售580百万美元，同比增长32%[12] - INGREZZA 2024年净产品销售指引上调至22.5-23.0亿美元[1,2] - 第二季度INGREZZA产品销售收入为5.838亿美元，同比增长30.8%[29] 研发进展 - NBI-1065845和Luvadaxistat的III期临床试验数据预计在第三季度公布[19] - 公司启动了多项新药物的I期和II期临床试验[19] - 公司在ENDO 2024大会上发布了crinecerfont III期临床试验的新数据[15] - 公司获得FDA对crinecerfont治疗先天性肾上腺增生症的优先审评[15] 销售团队及产品线拓展 - 公司计划扩大INGREZZA的精神科和长期护理销售团队[16] - 公司推出INGREZZA的新型颗粒剂型[16] 财务表现 - 公司报告第二季度总收入为5.902亿美元，同比增长30.4%[29] - 第二季度研发费用为1.911亿美元，同比增加31.1%[29] - 第二季度销售及管理费用为2.42亿美元，同比增加9.1%[29] - 第二季度非GAAP净利润为1.689亿美元，同比增长34.4%[34] - 第二季度非GAAP每股摊薄收益为1.63美元，同比增长30.4%[35] - 公司预计全年研发及销售费用合计将达到8.356亿美元[29] 其他事项 - 公司获得Medicare和Medicaid的特殊小型制造商豁免[15] - 公司完成可转换票据的全额现金偿还[15] - 公司与合作伙伴达成了2650万美元的里程碑付款[36] - 公司计提了1400万美元的租赁物业减值费用[36] - 公司结算可转换票据产生了4970万美元的费用[36]

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% YearOver-Year Growth Three Months Ended Six Months Ended INGREZZA® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion Top-Line Phase 2 Data Readouts for NBI-'568 and Luvadaxistat Remain On Track in Q3 SAN DIEGO, Aug. 1, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2024 and provided an update on its ...

The upcoming report from Neurocrine Biosciences (NBIX) is expected to reveal quarterly earnings of $1.15 per share, indicating an increase of 21.1% compared to the year-ago period. Analysts forecast revenues of $548.7 million, representing an increase of 21.2% year over year. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has ...

The market expects Neurocrine Biosciences (NBIX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

English check-icon Italiano Deutsch Français FX Empire Logo Español Português العربية Important DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial ...

"Only INGREZZA offers a sprinkle formulation to ease administration for individuals living with tardive dyskinesia or Huntington's disease chorea, who often have difficulty swallowing pills," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "We wanted to provide this new option to patients and their caregivers who want the benefit of treatment with INGREZZA without the challenge of swallowing a capsule." INGREZZA and INGREZZA SPRINKLE offer simple dosing that's always one capsule, ...

Conference Call and Webcast Scheduled for Thursday, August 1 The schedule for the press release and conference call / webcast is as follows: The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple pu ...